Soliton (NSDQ:SOLY) announced it has entered into a manufacturing services agreement with Sanmina to produce its rapid acoustic pulse (RAP) device for tattoo and cellulite removal and the treatment of fibrotic scars.
A limited launch is expected in mid-2020. Under the terms of the agreement, which is effective March 6, 2020, Sanmina will also manufacture the RAP devices’ replaceable cartridges.
“We are delighted to continue to partner with Sanmina Corporation as we begin our transition into the manufacturing phase of commercialization ahead of the planned mid-2020 limited launch of our unique RAP device,” said Soliton president & CEO Dr. Chris Capelli in a news release. “Sanmina’s expertise and world-class service are a great match for Soliton’s innovative device, which is FDA-cleared for tattoo removal and we believe has potential in additional aesthetic indications including cellulite removal and fibrotic scarring, and we look forward to working with them in the years ahead.”
Houston, Texas-based Soliton, which licensed the technology from the University of Texas on behalf of the MD Anderson Cancer Center in Houston, released the results of a clinical study of scar treatment in January.
The company’s rapid acoustic pulse device won 510(k) clearance from the FDA in May 2019. The company raised $9.5 million in a private placement in June, led by a $5 million investment by its largest backer, Remeditex Ventures.
